Related Experiment Video

Updated: Mar 31, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K

Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease

Jennifer G Goldman1, Neelum T Aggarwal2, Cynthia D Schroeder3

  • 1Rush University Medical Center, Department of Neurological Sciences, Section of Parkinson Disease & Movement Disorders, 1725 W. Harrison Street, Suite 755, Chicago, IL 60612, USA.

Neurodegenerative Disease Management
|October 31, 2015
PubMed

Insights

Mild cognitive impairment (MCI) in Parkinson's disease (PD) is a new research area facing definition challenges. Lessons from Alzheimer's disease (AD) research may guide future PD-MCI studies and treatments.

Area of Science:

  • Neuroscience
  • Neurology
  • Cognitive Science

Background:

  • Cognitive dysfunction is a key research area in Parkinson's disease (PD) and Alzheimer's disease (AD).
  • Mild cognitive impairment (MCI) is a recognized prodrome to AD, but MCI in PD (PD-MCI) is a newer construct with evolving diagnostic criteria and research programs.
  • Significant challenges and controversies exist regarding the definition, application, heterogeneity, and varied trajectories of PD-MCI.

Purpose of the Study:

  • To review current research advances and challenges in Parkinson's disease with mild cognitive impairment (PD-MCI).
  • To discuss lessons learned from Alzheimer's disease (AD) research, including evolving MCI/AD definitions, biomarker advancements, and therapeutic trial development, applicable to PD-MCI.

Main Methods:

  • Literature review focusing on recent research in PD-MCI.
  • Comparative analysis of MCI concepts and research strategies between PD and AD.

Main Results:

  • PD-MCI is a developing field with ongoing debates on its precise definition and characteristics.
  • The AD field offers valuable insights into MCI progression, biomarker discovery, and therapeutic strategies that can inform PD-MCI research.

Conclusions:

  • Further research is needed to refine the definition and understanding of PD-MCI.
  • Leveraging experiences from AD research can accelerate progress in diagnosing and treating cognitive impairment in Parkinson's disease.
Keywords:
Alzheimer's diseaseParkinson's diseaseamnesticbiomarkercognitivedementiadiagnostic criteriaexecutive functionmild cognitive impairmentnonamnestic

More Related Videos

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.4K
The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

34.2K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
702
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
836